Gateway to China: Developing Biologics for the Fastest-Growing Patient Population on Earth
Date: Thursday, January 12, 2023
Time: 9:30am CET / 4:30pm China time
Duration: 1 hour
China is the world’s second-largest pharmaceutical market, following the US, with a market share around 12% in global pharmaceutical sales in 2021.* With an aging population and the rise of new indications, this population makes an attractive market for any biopharmaceutical company. In this webinar, hear from Yan Fang Ma, general manager of Thermo Fisher’s site in Hangzhou, China, as she describes the opportunities and challenges multinational companies may face bringing biologics and sterile drug products to market in China and the how the right CDMO partner can provide trusted guidance along the way.
Join us for the webinar with Yan Fang Ma, vice president and site general manager for Thermo Fisher’s new CDMO site in Hangzhou, China.
- What makes China an attractive market for biopharmaceutical companies?
- What challenges do these companies face to develop and manufacture drugs in China?
- What factors to keep in mind when choosing a CDMO partner to enter the China market